Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10619757rdf:typepubmed:Citationlld:pubmed
pubmed-article:10619757lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:10619757lifeskim:mentionsumls-concept:C0038170lld:lifeskim
pubmed-article:10619757lifeskim:mentionsumls-concept:C0029443lld:lifeskim
pubmed-article:10619757lifeskim:mentionsumls-concept:C0007561lld:lifeskim
pubmed-article:10619757lifeskim:mentionsumls-concept:C1552617lld:lifeskim
pubmed-article:10619757lifeskim:mentionsumls-concept:C0282443lld:lifeskim
pubmed-article:10619757pubmed:issue1lld:pubmed
pubmed-article:10619757pubmed:dateCreated2000-3-9lld:pubmed
pubmed-article:10619757pubmed:abstractTextCeftriaxone, although less active than standard antistaphylococcal agents, is potentially useful in the treatment of osteomyelitis. Thirty-one patients with osteomyelitis due to Staphylococcus aureus were identified, 22 of whom were treated with ceftriaxone and 9 with other agents. Of those patients treated with ceftriaxone, 17 were cured; all treatment failures were associated with chronic osteomyelitis and continued presence of necrotic bone or infected hardware. It is concluded that ceftriaxone is effective in the ambulatory treatment of S. aureus osteomyelitis.lld:pubmed
pubmed-article:10619757pubmed:languageenglld:pubmed
pubmed-article:10619757pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10619757pubmed:citationSubsetIMlld:pubmed
pubmed-article:10619757pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10619757pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10619757pubmed:statusMEDLINElld:pubmed
pubmed-article:10619757pubmed:monthJanlld:pubmed
pubmed-article:10619757pubmed:issn1058-4838lld:pubmed
pubmed-article:10619757pubmed:authorpubmed-author:JacobyR KRKlld:pubmed
pubmed-article:10619757pubmed:authorpubmed-author:GuglielmoB...lld:pubmed
pubmed-article:10619757pubmed:authorpubmed-author:LuberA DADlld:pubmed
pubmed-article:10619757pubmed:authorpubmed-author:PalettaDDJrlld:pubmed
pubmed-article:10619757pubmed:issnTypePrintlld:pubmed
pubmed-article:10619757pubmed:volume30lld:pubmed
pubmed-article:10619757pubmed:ownerNLMlld:pubmed
pubmed-article:10619757pubmed:authorsCompleteYlld:pubmed
pubmed-article:10619757pubmed:pagination205-7lld:pubmed
pubmed-article:10619757pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10619757pubmed:meshHeadingpubmed-meshheading:10619757...lld:pubmed
pubmed-article:10619757pubmed:meshHeadingpubmed-meshheading:10619757...lld:pubmed
pubmed-article:10619757pubmed:meshHeadingpubmed-meshheading:10619757...lld:pubmed
pubmed-article:10619757pubmed:meshHeadingpubmed-meshheading:10619757...lld:pubmed
pubmed-article:10619757pubmed:meshHeadingpubmed-meshheading:10619757...lld:pubmed
pubmed-article:10619757pubmed:meshHeadingpubmed-meshheading:10619757...lld:pubmed
pubmed-article:10619757pubmed:meshHeadingpubmed-meshheading:10619757...lld:pubmed
pubmed-article:10619757pubmed:meshHeadingpubmed-meshheading:10619757...lld:pubmed
pubmed-article:10619757pubmed:meshHeadingpubmed-meshheading:10619757...lld:pubmed
pubmed-article:10619757pubmed:meshHeadingpubmed-meshheading:10619757...lld:pubmed
pubmed-article:10619757pubmed:meshHeadingpubmed-meshheading:10619757...lld:pubmed
pubmed-article:10619757pubmed:meshHeadingpubmed-meshheading:10619757...lld:pubmed
pubmed-article:10619757pubmed:year2000lld:pubmed
pubmed-article:10619757pubmed:articleTitleCeftriaxone therapy for staphylococcal osteomyelitis: a review.lld:pubmed
pubmed-article:10619757pubmed:affiliationDepartment of Clinical Pharmacy, School of Pharmacy, University of California San Francisco, San Francisco, CA 94143-0622, USA. bjg@itsa.ucsf.edulld:pubmed
pubmed-article:10619757pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10619757pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10619757lld:pubmed